A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
NCT07403188
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Refractory Lupus Nephritis
- Myasthaenia Gravis
- Stiff Person Syndrome
- Rheumatoid Arthritis (RA)
- Multiple Sclerosis
- Dermatomyositis
- Systemic Sclerosis (SSc)
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Kyverna Therapeutics
- Last updated on ClinicalTrials.gov
- February 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- University of Colorado, Denver · Denver, CO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.